Compare BMR & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMR | BYSI |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1M | 58.4M |
| IPO Year | 2021 | 2016 |
| Metric | BMR | BYSI |
|---|---|---|
| Price | $1.83 | $1.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 72.0K | 12.3K |
| Earning Date | 02-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $1.18 |
| 52 Week High | $4.32 | $3.44 |
| Indicator | BMR | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 50.01 |
| Support Level | $1.89 | $1.46 |
| Resistance Level | $1.97 | $1.75 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 60.99 | 69.89 |
Beamr Imaging Ltd provides content-adaptive video compression solutions for human viewing and machine vision. The company is trusted by technology companies such as NVIDIA and Amazon Web Services, and serves media companies including Netflix, Paramount, and JioHotstar. Using Emmy-winning patented technology, its solutions help deliver media content with high quality while reducing storage and delivery costs. Its customers include over-the-top content distributors, video streaming platforms, and Hollywood studios that use its products to store, distribute, and monetize video and images across devices. The company operates in the United States, Israel, and the rest of the world, with the United States generating maximum revenue.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.